Autonomix Medical, Inc.
AMIXNASDAQHealthcareMedical - Devices
Previous close
$5.27
$0.00 · 0.00%
Pre-market
$5.69
+$0.42 · +7.97%
Aug 24, 6:27 AM ET
AMIX company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
45
Fair Value
Momentum
19
Strong Down
Sentiment
51
Mixed
Risk resilience
34
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteAutonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. The company’s technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Medical, Inc. was incorporated in 2014 and is headquartered in The Woodlands, Texas.
- Industry
- Medical - Devices
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Bradley A. Hauser
- Listed since
- Jan 29, 2024
- Employees
- 10
Market position
Day range
Current $5.27
52-week range
Current $5.27
- Open
- $5.19
- Previous close
- $5.27
- Volume
- 109.84K
- 0.07× average
- Average volume
- 1.57M
- Average daily volume
- Market cap
- 2.86M USD
- Beta
- -1.3
- Market reference 1
- 50-day average
- $6.5889
- -20.02% below average
- 200-day average
- $9.7293
- -45.83% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- -4.19M USD
- P/E (TTM)
- -0.11×
- P/B (TTM)
- 0.91×
- P/S (TTM)
- 0×
- EV / EBITDA
- 0.25×
- Earnings yield
- -593.88%
- Free cash flow yield
- -436.73%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -283.55%
- Return on assets
- -219.93%
- Return on invested capital
- -288.96%
Financial health
- Debt / equity
- 0×
- Current ratio
- 4.45×
- Altman Z-score
- -34.93
- Piotroski F-score
- 2 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Cost of goods sold | 12K USD | — | — | — | — |
| Gross profit | −12K USD | — | — | — | — |
| Research and development | 7.14M USD | 4.73M USD | 2.23M USD | 745K USD | 4.07K USD |
| Selling, general, and administrative | 9.89M USD | 6.86M USD | 5.25M USD | 1.25M USD | 13.59M USD |
| Operating expenses | 17.02M USD | 11.59M USD | 12.03M USD | 1.99M USD | 13.59M USD |
| Interest income | 319K USD | 354K USD | 127K USD | — | — |
| Interest expense | — | 176K USD | 79K USD | — | 218.09K USD |
| Depreciation and amortization | 12K USD | 183K USD | 81K USD | — | — |
| Operating income | −17.03M USD | −11.59M USD | −12.03M USD | −1.99M USD | −13.59M USD |
| Net income | −16.72M USD | −11.41M USD | −15.43M USD | −1.99M USD | −13.33M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 29%
- 2 beats, 2 misses, 3 met estimates
- Average EPS surprise
- -5.70%
- 7 comparable reports
- Latest EPS result
- -5.02
- Estimate -6.4 · Beat by 21.56%
EPS: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Recent analyst actions
AMIX news
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jun 24, 2026 | 1:21 | — | — |
Effective Jun 24, 2026
1:21
AMIX peers
Continue in GoAI
Research AMIXresearch.disclaimer